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Background: When a child participates in a clinical trial, informed consent has to be given by the parents. Parental
motives for participation are complex, but the hope of getting a new and better treatment for the child is
important. We wondered how parents react when their child is allocated to the control group of a randomized
controlled trial, and how it will affect their future engagement in the trial.
Methods: We included parents of newborns randomized to the control arm in the Danish Calmette study at
Rigshospitalet in Copenhagen. The Calmette study is a randomized clinical trial investigating the non-specific effects
of early BCG-vaccine to healthy neonates. Randomization is performed immediately after birth and parents are not
blinded to the allocation. We set up a semi-structured focus group with six parents from four families. Afterwards
we telephone-interviewed another 19 mothers to achieve saturation. Thematic analysis was used to identify themes
across the data sets.
Results: The parents reported good understanding of the randomization process. Their most common reaction to
allocation was disappointment, though relief was also seen. A model of reactions to being allocated to the control
group was developed based on the participants’ different positions along two continuities from ‘Our participation
in trial is not important’ to ‘Our participation in trial is important’, and ‘Vaccine not important to us’ to ‘Vaccine
important to us’. Four very disappointed families had thought of getting the vaccine elsewhere, and one had
actually had their child vaccinated. All parents involved in the focus group and the telephone interviews wanted to
participate in the follow-ups planned for the Calmette study.
Conclusions: This study identified an almost universal experience of disappointment among parents of newborns
who were randomized to the control group, but also a broad expression of understanding and accepting the idea
of randomization. The trial staff might use the model of reactions in understanding the parents’ disappointment
and in this way support their motives for participation. A generalized version might be applicable across
randomized controlled trials at large.
Trial registration: The Calmette study is registered in EudraCT (https://eudract.ema.europa.eu/) with trial number
2010-021979-85.
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Before patients participate in a clinical trial they must give
signed informed consent stating that they understand and
accept the terms of the trial [1]. For randomized con-
trolled trials (RCTs) this also means understanding and
accepting that there is a probability, most often 50%, of
being allocated to the control group thus receiving no
treatment, placebo, or standard treatment. In general, pa-
tients often struggle to understand the study design of an
RCT; the concept of randomization and its implications
can be difficult to understand and accept [2].
Several studies have investigated patients’ motives for
participating in clinical trials and found that altruism
along with the hope of personal gain were the dominant
motives among the patients [3-5]. The hope of personal
gain is probably tied up with being allocated to the treat-
ment group, rather than the control group [6]. If pa-
tients in general hope to receive the active treatment, it
is reasonable to assume that they will feel disappointed
if allocated to the control group, but few studies have ac-
tually addressed this issue. In a smoking cessation trial
expressions of disappointment were common and drop-
out rates tended to be higher in the intervention group
compared to the control group, although not statistically
so; the most dissatisfied were those who did not under-
stand the study design [7]. In contrast, in a trial in
rheumatic diseases, patients who were lost to follow-up
more often stated personal issues as the reason rather
than dissatisfaction with the trial [8].
When the patient is a child, informed consent has to
be given by the parents, which places the parents in a
difficult situation since their role is to protect and care
for the child. When being asked to participate in a ran-
domized trial, parents do not only have to balance the
risks against the potential benefits as if they were to be
research subjects themselves, but furthermore they have
to make the ‘right’ decision on behalf of their child in
order to feel like good parents [9]. Their motives for let-
ting the child participate are therefore likely to be com-
plex. The hope of getting a new and better treatment is
important [2,10], but parents also see the decision about
trial participation as an important responsibility and find
it appropriate that they are asked for their consent, even
though it remains a difficult decision [11].
Parents’ reactions to and understanding of their child’s
allocation in an RCT were studied qualitatively at the
end of a trial where severely ill newborns were allocated
to conventional treatment or to transferal for extracor-
poreal membrane oxygenation [2]. Interviews were car-
ried out before the results of the RCT were known.
Parents of children in the control group expressed disap-
pointment because continuing standard intensive care in
a situation of life-threatening illness was viewed as doing
nothing. A later study was conducted with a differentgroup of parents from the same trial after the parents
had been told that the RCT had shown extracorporeal
membrane oxygenation to be effective and to save lives
[12]. After this new information, the parents of the inter-
vention group objected to the concept of randomization
since they thought that the intervention had saved their
child, whereas the parents of the ‘standard care’ group
had experienced that their child had survived without
intervention and consequently were less critical of the
concept of randomization.
We wondered how parents react when their child is al-
located to the control group in a less critical context. Do
they feel disappointed or relieved, and how do they cope
with their emotional response? We also wondered if
their way of coping influences their motivation towards
the continued participation in the trial.
To answer these questions we set up a qualitative
study including parents of children who were allocated
to the control group of the Calmette study at Rigshospi-
talet, Copenhagen.
The Calmette study
The Danish Calmette trial is an ongoing randomized
controlled clinical trial, taking place from 2012 to 2015
in three hospitals in Denmark, and aiming to enroll
4,300 newborns from the general population and
randomize them to BCG (Calmette) vaccination versus
no intervention. The BCG vaccine was withdrawn from
the Danish Child Vaccination Program in 1982 when
protection against tuberculosis was no longer relevant
since the incidence of tuberculosis in Denmark had be-
come low. The adherence to the Danish Child Vaccin-
ation Program is generally good with, for example, 91%
to 94% of the newborn population immunized with the
diphtheria, tetanus, pertussis, polio, and haemophilus
influenza vaccine at ages 3 months, 5 months, and
12 months. The Calmette-study investigates the poten-
tial positive non-specific effects of early BCG vaccine in
high-income settings. The hypothesis tested in the
Calmette-study is if the BCG vaccine, besides the spe-
cific protection against tuberculosis, causes a general,
non-specific modulation of the immune system that
could reduce infectious diseases in the first years of life
as well as the incidence of atopic dermatitis, asthma,
and allergies [13], as recently documented in low-
income settings in West Africa [14]. The BCG vaccine
has been widely used globally since 1921 and side effects
are well known and described [15]; the risk of severe
side effects is small [16]. After vaccination, a characteris-
tic sore usually develops at the injection site lasting two
to four months, resulting in a small scar [17]. Therefore,
the parents in the Calmette-study were not blinded to
the allocation as no suitable placebo mimicking the sore
and scar exists.
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pregnancy, but randomization was delayed until after
the infant was born. Written information about the
study was sent to the parents by mail in the beginning of
the third trimester of the pregnancy, including an infor-
mation sheet explaining the background, aims, course,
side effects, and potential benefits and risks along with
information about the general rights of participants in
biomedical trials (Additional file 1). A couple of weeks
later, the family received a phone call from a member of
the research team in order to elaborate on the informa-
tion sheet and to discuss participation in the trial. The
parents were given the opportunity to consider partici-
pation and get in contact with trial staff as many times
as they needed before giving their informed consent. If
the parents decided to participate, they signed the consent
form that had been sent along with the written informa-
tion, and mailed it to the trial staff. Written informed con-
sent could also be given at the hospital. A few hours after
delivery, the midwife in charge or the Calmette study re-
search staff performed the computerized randomization,
and children allocated to the active group were vaccinated
immediately whereas children allocated to the control
group received no intervention. All personnel performing
randomization and the intradermal BCG-injection were
specially trained in the procedures. If, for some reason,
randomization was postponed, the child could still be ran-
domized (and immunized if allocated to the active group)
within 7 days of birth.
Methods
The subjects were parents of children participating in
the Danish Calmette study who had been allocated to
the control group. Hence, we did not contact parents of
children allocated to the intervention group. We
planned a focus group with eight families, but only four
families took part and we subsequently conducted semi-
structured telephone interviews with an additional group
of 19 mothers based on the preliminarily identified
themes of the focus group [18]. The recruitment process
















Figure 1 Flow chart of the recruitment process.Focus group
We contacted the parents of the children, but we only
had the mothers’ telephone numbers, not the fathers’.
For the focus group, both parents were encouraged to
participate. We contacted the mothers according to the
birth date of the child, starting with the youngest first.
We did not contact mothers of children younger than
one month. As a preparation we sent an e-mail with
seven unfinished sentences (Table 1) to reflect upon – if
possible between the two parents. The unfinished sen-
tences were designed to give the parents an idea of what
kind of questions we were going to discuss and give
them an opportunity to form their own thoughts and
opinions before entering the group.
We called the mothers of 40 infants who were con-
secutively enrolled in the Calmette study and achieved
verbal contact with 34, 8 of which agreed to participate
in the focus group. All of the mothers actually wanted to
help, but either they had other plans at the time of the
focus group or they said that it was too stressful to have
to show up at a certain place on a certain time when the
child was still so young. Two mothers cancelled a couple
of days before the focus group and two mothers can-
celled on the day of the focus group. The reasons were
problems with breastfeeding, child going to the doctor,
and that it was too stressful to have to show up. We
tried to invite new mothers when the first two mothers
had cancelled but it was not possible at such short no-
tice. The focus group was therefore conducted with four
mothers (M1 to M4), and two fathers (F1 and F2); the
two fathers who did not attend were at work. The focus
group took place approximately 5 weeks after delivery
and randomization.
The interviewer (VZ) and two observers (SMP and
GG) were present. The interviewer, a person unrelated
to the Calmette study, followed a semi-structured form
based on the seven unfinished sentences (Table 1). We
addressed the questions of why the parents had decided
to participate in the Calmette study, how they experi-
enced the randomization process, how they had reacted










interview (n = 4)
Not achieved 




Table 1 Unfinished sentences for the focus group interview and questions for the telephone interviews
Focus group interview - unfinished sentences Telephone interviews - questions
1. When we agreed to let our child participate in the
Calmette study the most important reason was…
1. What was your most important reason for participating in the study?
2. After signing the consent we thought… 2. How were you informed that your child was in the control group? When (counted in
hours after the child’s birth) were you informed?
3. What worried us the most was… 3. Was it clear to you beforehand that it was a random process, whether your child
was getting the vaccine or not? What do you think about that?
4. Immediately after we were told that our child
was not going to be vaccinated, we thought…
4. What was your immediate reaction to being told that your child was not getting
the vaccine?
5. What we are most delighted of now is… 5. What do you think now that you have had some time to consider the fact that your child
is in the control group? Have you done anything on that note?
6. What we are most annoyed with now is… 6. What do you think of your continued participation in the study? Is there anything that
has made you wonder?
7. What we still don’t understand is…
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present to take notes and observe non-verbal data. The
focus group session lasted one hour and fifteen minutes.
It was audio-recorded and afterwards a transcription
was carried out by SMP.
Telephone interviews
When recruiting for the focus group, it became clear
that the majority of the mothers could not find time or
energy to attend a focus group because of their child be-
ing so young. Some of them even asked why we could
not just interview them over the phone which we conse-
quently did. For practical reasons, we only talked with
the mothers of the children, not the fathers. We called
29 of the 30 women who had been invited without at-
tending the focus group, and we gave them at least one
call. The one who was not contacted was excluded be-
cause she did not speak Danish. We achieved verbal
contact with 23 mothers of which 19 were telephone
interviewed (TM1 to TM19) including two of the four
mothers who initially were supposed to participate in
the focus group but who had cancelled. The four women
who did not participate were all willing to complete the
interview but were busy at the time of the phone call.
Saturation was achieved after approximately 15 inter-
views, and having completed 19 interviews, we saw no
need for contacting the last four women again.
The interview involved questions regarding demo-
graphical background and experiences with participation
in the trial (Table 1). The interviews took place between
9 and 12 weeks after delivery and randomization.
Demography
The age of the mothers in the study ranged from 25 to
42 and the fathers from 25 to 46. In two cases, the father
was an unknown donor. All mothers, except one, had
higher education. Ten of the mothers had children be-
fore the present one (range 1–8). The women had been
in verbal contact with a member of the Calmette staffbetween 0 and 3 times before signing the consent form.
The parents all lived in the metropolitan area of
Copenhagen.
Analysis of data
The focus group transcription was re-read several times
by SMP in order to get familiarized with the data. Based
on a preliminary inductive analysis of these data, a set of
six open questions was developed to approach the most
important topics as identified with the focus group. In
this way the focus group inspired the subsequent tele-
phone interviews. Notes made by SMP during the tele-
phone interviews were transcribed afterwards and
initially coded separately. Subsequently, we used induct-
ive thematic analysis to identify important themes across
the two data sets [19]. This meant searching for themes
and patterns through the entire data corpus and the gen-
erated codes. For each identified theme, all the relevant
data were found and grouped. Afterwards, the themes
were gathered in mind maps to visually analyze how the
different themes worked together, to fuse themes that
covered the same aspect of the problem and to erase
themes that were irrelevant. Data were organized in
Microsoft Word.
Disappointment was an overarching reaction among
participants. Further analysis revealed that the degree of
the parents’ disappointment was connected with their
positions on two continuities moving from ‘Vaccine not
important to us’ to ‘Vaccine important to us’, and from
‘Our participation in trial is not important’ to ‘Our par-
ticipation in trial is important’ (Figure 2). All analyses
were performed by SMP and supervised by VZ.
Ethics
The Calmette study is registered in EudraCT (https://
eudract.ema.europa.eu/) with trial number 2010-021979-
85 and was approved by the Danish National Committee
on Health Research Ethics (approval number: H-3-2010-









Our participation in trial is not important 
Our participation in trial is important 
My motivation has 
gone down.
We have had the 
vaccine elsewhere.
My child in specific
would have benefitted 
from the vaccine.
After so much 
consideration ending 
up not getting it!
Are we in the trial at 
all?
We’ve not been giving 
it attention since we’re 
controls.
I would have been 
more worried if child 
got it.
Children in general do 
well without.
We’re supporting 
science with no risk.
Our child is healthy 
and we expect no 
problems.
We’re still getting 
special attention.
It’s going to be 
interesting to see the 
results.
Maybe our next child 
will benefit.
Figure 2 Reactions from parents of newborn infants who were randomized to the control group. The newborns participated in a vaccine trial
and parents were not blinded to the allocation. Most of the parents were disappointed with the allocation; disappointment was followed by reactions
that differed in degree and which could be positioned along the two continuities of this diagram.
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ject to ethical review board approval, so the present
study did not need another specific ethical clearance.
Results
Circumstances of the allocation process
Either a midwife or a member of the research staff told
the parents that their child was going to be randomized,
and the outcome was revealed immediately afterwards.
In most cases of uncomplicated deliveries this took
place in the delivery room and in a few cases the next
day in the maternity ward. In general, the parents de-
scribed the allocation process as non-stressful and said
that it did not disturb the new family. When compli-
cations during labor affected either the child or the
mother, parents were not approached until later, but the
experience of the randomization process did not differ
markedly for them.
Three families were familiar with the fact that their
child had not received the vaccine but were uncertain as
to whether their child was still a part of the Calmette
study. Two of them had experienced post-partum
bleeding and had been transferred for operation shortly
after the child’s birth and thought that the personnel
had postponed information about allocation, and that
it eventually had been forgotten:
“We somehow wondered if it had been recorded that
he had been born.” (TM9).Of the 23 families we interviewed, 21 said they had
understood that it was a random process that decided
whether the child got the vaccine or not. Most said that
they considered the random process as fair, and that they
accepted that those allocated to the control group would
not get the vaccine. Their acceptance was not necessarily
based on an understanding of the rationale for randomi-
zing but rather on an acceptance of randomization as a
tool that researchers use:
“It is a scientific trial, and this is the way you do these
things.” (F2).
The sentence “That’s the way it is” was repeated by
many parents.Some parents made comments suggesting
that they did not completely understand the importance
of their child in the study when it was randomized to
the control group, even if they said they understood.
“(…) of course it was a shame that we weren’t really
participating, but then again there were so many other
things to think about.” (TM11).
Two families had problems understanding the study de-
sign as a randomized controlled trial. One mother said
that she had forgotten to inform the father of the child
about the randomization part. He had not spoken with
the research staff beforehand, but based on the mother’s
explanation he had understood that agreeing to participate
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understanding was not corrected until randomization was
performed, and the child was allocated to the control
group. Another mother said in the beginning of the inter-
view that she was aware that her child might or might not
get the vaccine, but later she wondered if her child did not
get the vaccine because it was born during the night. She
thought that the research group might have chosen to vac-
cinate only children born during daytime, when study staff
was present.Disappointment or relief? – Immediate reactions
to allocation
Parents of 21 out of 23 children expressed that they had
hoped their child would receive the vaccine, especially
because of the potential benefit of protection against
atopic disease, but also a hope of protection against dis-
eases in general was also mentioned. A few mentioned
that protection against tuberculosis would be nice to
have if their child was to travel later in life.
“If you can have a child with an optimized health, it is
fantastic, and it sounds like you could. That’s your
hypothesis – and of course also that it didn’t imply
any serious risks.” (TM10).
The parents judged the risk of participation from very
small to non-existing. The fact that the vaccine had been
used for many years and that the risk of side effects was
known to be small was an important reason for wanting
to participate.
“There weren’t any side effects, otherwise you wouldn’t
dare. It is something that has been tried before, so
there couldn’t be anything wrong in trying it.” (T5).
The most common immediate reaction to the allocation
was disappointment, but the degree of disappointment
varied greatly. Most parents described pure disappoint-
ment whereas some felt ambivalent or had an immediate
feeling of relief followed later by disappointment. Some
were very disappointed:
“My immediate [reaction] was a, a “crap” or
“damn”…” (M4).
This parent had spent a lot of time and energy dis-
cussing the allocation at home whereas other parents
described their disappointment as a very short lasting
emotion that was soon forgotten because of all the other
events surrounding them as new parents.
Of the few women who did not express disappoint-
ment, one said that she felt relieved. Her child had beenadmitted to the neonatal department, and the worries
that this might cause could well be an explanation.
By way of summing up, the parents’ diverse reactions
to having their child allocated to the control group pro-
vided evidence for developing a model based on their
positions on two continuities moving from ‘Vaccine not
important to us’ to ‘Vaccine important to us’, and mov-
ing from ‘Our participation in trial is not important’ to
‘Our participation in trial is important’ (Figure 2).
How important is the vaccine to us?
The parents who expressed frustration were often deeply
engaged, either because they thought their child in par-
ticular would have benefitted from the vaccine, or be-
cause they had thoroughly considered and spent long
hours deciding whether or not to participate.
Some of the parents were themselves affected by atopic
diseases and were aware of the burden of the disease to
which their children would be predisposed. These parents
were disappointed by the allocation to the control group.
This was expressed by a mother with atopic dermatitis
who, despite having an immediate feeling of relief after al-
location, later became aware of her disappointment:
“Well, I kind of thought that, well in the beginning I
thought: ‘Hmm, but that’s fine. Then he doesn’t have
to be hurt by a needle and the scar and such, well, all
such…’ And now I (…) think: ‘Hey, maybe I’m actually
upset, because of the fact that it might have helped
him, right?’ (…) so I would have liked that he got it, if
it meant that he doesn’t have to suffer with the things
I have now.” (M1).
A parent of a child who had suffered from common
colds expressed that she – despite immediate relief –
now could not stop thinking that he might have avoided
all that trouble if he had had the vaccine.
Parents who had spent time deciding whether or not to
participate and hence invested emotions in the decision
also expressed frustration. They had usually been in tele-
phone contact with personnel from the research group
more than once. Some had involved friends and family in
order to decide, and one woman even described how her
entire family had been against their participation.
“I had a couple of friends who didn’t want it (…) I was
at a family birthday party and everybody thought
that… that we shouldn’t do it. (Laughs)” (M2).
Parents who in this way had put time and energy into
making the decision to participate described that the
choice of participation in reality was an acceptance of
the vaccine. Allocation to the control group was conse-
quently felt to be a great waste of time and energy.
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decision to participate, and… considered all the things
that could be negative and weighed it against the
positive…” (M1).
“That’s it!” (M2).
“…then it’s a little… Hey, then you would have liked
to… Now you have made all these decisions, so
you would have liked to be, like, really participating.”
(M1).
In contrast, mothers who either said that they had not
given the fact that they were in the control group much
thought and had no special reason to want the vaccine,
would often argue that their child probably would not
have benefitted from the vaccine.
“If he had been sick, I might have thought more about
it and be even more annoyed about not being a part
of it, because it might have prevented something.”
(TM14).
For some parents a smaller degree of disappointment
also implied a neutral interest in following the results of
the investigation as expressed:
“Now we just want to follow the results of the
investigations, you’re doing. We haven’t had any
problems with her with diseases, such as asthma, and
don’t expect to, so we’re just eager to follow the
results.” (TM16).
Only two parents expressed indifference concerning
getting the vaccine, one arguing that she had only partic-
ipated ‘to help science’, and the other saying that her
primary reason for letting her child participate was the
fact that participation could not have negative conse-
quences; neither of them was disappointed.How important is my child to the trial?
Some parents expressed that they did not feel as import-
ant in the trial as they would have been if they had been
allocated to the treatment group. They did not feel as a
part of the study and they did not understand what their
role was in the control group.
“I would like to contribute, but I also think that the
control group in this context is… It’s wrong to say less
essential, because I know that there has to be a control
group but… I’m also aware that there will be a lot of
others, so there will be… others who can form the
control group and (…) How come you don’t use, as en
extra sort of control group, all the babies that… Thatare just ordinary, that are not in the study in any
way.” (M4).
“The most interesting are those that participate by
getting the vaccine.” (TM10).
Others did not feel important in the trial either, but as
they had not made a big investment in participation,
they did not give their allocation much thought even
though they had hoped for the intervention group.
“(…) of course it was a shame that we weren’t really
participating, but then again there were so many other
things to think about.” (TM11).
Others said that it made them feel good to be part of a
trial and to contribute to science, meaning that they
understood that they played a part in the trial even
though they did not get the vaccine.
“We contribute anyway. It means a lot that there is a
control group.” (TM6).
Their disappointment was not so dominant, since they
found participation meaningful.
“Of course one hoped that he would be vaccinated, but
it will also help in the future, if it is found that it was
beneficial.” (TM9).Conflict between the wish for intervention and the need
for a control group
Three of the most disappointed families considered get-
ting the vaccine elsewhere, and one of them had actually
tried to get it:
“But then I want to have the opportunity to give it to
her via the private sector. And it looks like it is damn
difficult. It makes me pissed. I think it is paternalistic!”
(M4).
The fact that they would not contribute to science if
they got the vaccine elsewhere did not play an important
role in this consideration. A family that had their child
vaccinated at three days of age by their family doctor
told a different story. The mother was not discontent
with their allocation, because the parents had simply de-
cided before the child’s birth that they wanted the vac-
cine no matter what, since the mother originated from a
country where all children are vaccinated at birth. They
had arranged with their family doctor that he would give
the child the vaccine in case they were allocated to the
control group. The mother said that she participated in
the Calmette study partly to get the vaccine, but also
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was nice when people said yes to participation. She was
not discontent with being allocated to the control group,
because she knew that it was a possibility when partici-
pating in a trial.
Adherence and future participation
None of the parents involved in the focus group or tele-
phone interviews said that they would not participate in
the follow-up planned in the Calmette study. Even the
couple that had had their child vaccinated by their fam-
ily doctor was happy to participate. One mother said
that her motivation had decreased but that she would
still participate as it was her civic duty. One of the par-
ticipants of the focus group said that it had been a very
good experience, emphasizing the importance of some
kind of follow-up after randomization.
“(…) I just think that it was really nice that there
was a follow-up, about what you, what kind of
considerations you can have afterwards. Because I
think it can… It can also mean that you can have a,
maybe a better talk with the parents who end up in
this control group (…).” (M3).
Discussion
We found an almost universal expression of disappoint-
ment among parents of children who were randomized
to the unblinded control group and had no intervention.
However, the study also reflected general understanding
and acceptance of the idea of randomization, and in
some cases altruism. A few families had considered hav-
ing their child vaccinated anyway, and one family actu-
ally did so. All families intended to participate in the
study follow-up.
Why did the parents in this study express such good
understanding of the random part of the RCT? Perhaps
most importantly, all participants were well informed
about the randomization process both in writing and or-
ally before entering the trial. Moreover, the educational
level of the participating families was high. A high level
of education has been associated with better understand-
ing of randomization [20,21], but not always so [22], and
participants of all educational levels struggle with under-
standing it [23]. We asked the mothers participating in
the focus group and the telephone interviews if they
understood the random process. Maybe we would have
found a poorer degree of understanding if we had asked
the parents how allocation had been decided upon. Pa-
tients may not understand the study design, even though
they feel well informed [2,20]. Finally, the parents in this
study were given ample time to make up their minds
about participation and the benefits of prevention of
common diseases. Therefore, the circumstances weredifferent from what parents have to face in acute and
critical situations and this affects acceptance as well as
understanding [2,22,24].
Most of the parents in this study had a preference to-
wards one of the treatment arms and were therefore not
in equipoise when entering. The parents describe how
they perceive the risks to be small and the potential
benefit to be large. Not surprisingly, the parents most
willing to participate are those who believe the benefits
of trial participation outweigh the risks [10,24-26]. It is
noteworthy, however, that parents who are given time to
think before the decision to enter their child in an RCT,
as was the case in this study population, are likely to be
more aware of the risks of participation [27,28].
It is argued that in a trial it is both possible and fair to
get informed consent from parents/patients, even if they
assume that the new treatment is better as long as they
are well informed about the randomization and potential
benefits and harms [24]. Many interventions tested in
RCTs point in the direction that the benefits outweigh
the harms, but that the existing evidence is still not
strong enough to make the intervention ‘standard care’.
In such situations, participants have good reason to pre-
fer intervention to non-intervention. Nevertheless, if
those randomized to the control group are significantly
disappointed it may threaten participation in follow-ups,
and it may also threaten the trial if control participants
are able to get the intervention from elsewhere. If partic-
ipants randomized to the control group are very dis-
appointed it may also call in question whether the
information given before consent was reasonably bal-
anced. It may threaten the trust-relation between the
community and the medical research establishment if in-
terventions perceived as clearly beneficial are tested in
placebo controlled RCTs.
A way of coping with parents’ disappointment when
their child is randomized to the control group is to
emphasize the important role of their child as a control
and appeal to the parents’ altruistic motives for partici-
pation. Even though the benefits to the child seem to be
of utmost importance to parents, it has previously been
shown that parents also give altruism as a major motive
for participation [29-31]. It is therefore important to
make it clear to the parents that the control group is
precisely as important for the trial as the intervention
group.
When informing parents that their child has been ran-
domized to the control group it is possible to explore
the parents’ understanding of the potential benefits and
harms of the experimental intervention. The model we
developed on the basis of the parents’ reaction to having
their child allocated to the control group might, in a
generalized version (Figure 3), serve as a tool for the use






My participation in trial is not important 
My participation in trial is important 
Figure 3 Reaction to allocation to the control group in randomized clinical trial. A tool designed to identify parents at risk of non-satisfaction,
and thereby at risk of non-compliance or drop-out.
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drop-out. It can be used in two ways: i) before the par-
ents agree to participate in the trial, they are to be asked
to place themselves in the diagram (Figure 3), trying to
imagine that their child is allocated to the intervention
group as well as to the control group; and ii) after alloca-
tion, the parents can look at the diagram and determine
where they see themselves in the study. If the parents in
either of the two situations place themselves extremely
positively along the x-axis or extremely negatively along
the y-axis, the researcher should review the trial informa-
tion sheet with them in order to give them the best pos-
sible understanding of the trial. If the tool is used after
allocation and the parents experience the trial information
sheet as new information, the information given before in-
formed consent may have been insufficient.
Such a tool needs further development and testing, and
may also prove valuable for RCTs in the recruitment of
consenting participants. The tool was developed too late
for us to formally test it in the Calmette study, but the
preliminary results of the present study made our team
realize the importance of strengthening the feeling of
identity and purpose in the control group by emphasizing
to parents the essential role their child plays in gaining
new insight. In the future, it would be interesting to
evaluate the benefits of this tool by qualitative studies. By
embedding such a tool in an RCT, it could be examined
if study adherence in the control group can be improved.
As shown in this study and in the available literature,
there is a lack of general knowledge about RCTs and
what it means to participate in an RCT. This is of public
interest since every citizen may be asked to participate
in an RCT. One woman said that she participatedbecause she considered it her ‘civic duty’. There could be
more public focus on clinical trials. The topic could, for
example, be part of the school curricula. First of all, it
would be beneficial for the individual who would find
her/himself to better able to decide, but it may also
benefit science itself if participants were better educated.
Strengths and limitations
This study has several strengths. Most importantly, it in-
vestigates the participants’ reactions after being allo-
cated, whereas most of the literature has investigated the
events leading up to allocation, namely the motives for
participation before entering, the understanding of the
randomization process, and problems with the informed
consent. We set up a focus group and made 19 telephone
interviews. We telephone-interviewed parents that could
not participate in the focus group to keep selection bias as
low as possible and we ended up having a satisfying rate of
participation among the women we achieved verbal con-
tact with. Through the telephone interviews we accom-
plished saturation. Finally, we interviewed the parents
relatively shortly after randomization to minimize prob-
lems with recalling thoughts and reactions.
Our study has limitations. Regarding the study popula-
tion, the parents investigated in this study may differ
from the general population. They were well educated
and all live in the metropolitan area of Copenhagen.
Two of the mothers got pregnant using an anonymous
donor. This may represent a selection bias in Rigshospi-
talet’s part of the Calmette study since, at the time of the
interviews, 40% to 50% of the families approached by
the Calmette study agreed to participate. Two fathers
participated in the focus group, but we only talked to
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cluded the mothers who picked up their phone and had
time for an interview immediately or at a later time the
same week. Altogether, we obtained information from 23
out of the 40 mothers we initially tried to achieve verbal
contact with, and they could differ from the 17 who did
not participate. The mothers who were included might
be the most disappointed who hence had interest in
sharing their frustration.
We did not interview parents of children allocated to
the intervention arm of the Calmette study, and therefore
we are not able to determine whether the reactions of par-
ents differ among the arms. We talked to parents of
mostly healthy children; the findings in our study might
have been different had we talked to parents of children
who were ill [10]. Our study therefore addresses the atti-
tudes and reactions of parents of healthy children rather
than parents of children who were ill. Furthermore, our
findings regarding parents of newborn children would not
necessarily apply to parents of older children.
Conclusions
This study identified an almost universal experience of
disappointment among parents of newborns who were
randomized to the control group in a study of BCG vac-
cination at birth. The understanding and acceptance of
the randomization process were good, probably due to
the comprehensive information material, the high level
of education, and the ample time available for the infor-
mation and consent process before birth. Based on the
findings in this study, we suggest that exploring and cor-
recting the parents’ understanding of the intervention,
including uncertainty of beneficial effect, as well as po-
tential harms, might lessen the feeling of disappoint-
ment. A useful way for research staff of dealing with the
disappointment may be to emphasize the important role
of the child in the control group and hence to appeal to
the altruistic motives for participation.
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